Background: While hylan G-F 20 is an approved therapy for the treatment of knee osteoarthritis, there are few reports of its use in shoulder osteoarthritis.
Hypothesis: Hylan G-F 20 can reduce pain and improve function in patients with glenohumeral osteoarthritis.
Study Design: Case series; Level of evidence, 4.
Methods: Thirty consecutive patients with idiopathic glenohumeral osteoarthritis who failed to respond to standard conservative measures were enrolled. Patients received 3 weekly intra-articular hylan G-F 20 injections in their affected shoulder and completed a visual analog scale for pain, the UCLA score, and the Simple Shoulder Test at baseline and at 1, 3, and 6 months after the third injection.
Results: Of the 30 patients, 3 withdrew during the washout period before treatment; the remaining patients (17 men and 10 women) had an average age of 62 years. The mean baseline visual analog scale score was 54, UCLA score was 15.7, and Simple Shoulder Test score was 5.7 (of 12 possible “yes” responses). At the 6-month follow-up, hylan G-F 20 significantly improved visual analog scale (mean 30, P < .001), UCLA (mean 24, P < .001), and Simple Shoulder Test (7.6 “yes” responses, P < .001) scores. More patients slept comfortably after treatment (56%) versus before treatment (15%). Nine patients had a visual analog scale improvement >40 points after 6 months. No device-related adverse events were observed.
Conclusion: Hylan G-F 20 may have a beneficial therapeutic effect on some symptomatic patients with glenohumeral osteoarthritis.
American College of Rheumatology Subcommittee on Osteoarthritis Guidelines: Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum.2000;43: 1905-1915.
3.
American Pain Society.Guidelines for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis. Glenview: American Pain Society; 2002.
4.
Amstutz HC, Sew Hoy AL, Clarke ICUCLA anatomic total shoulder arthroplasty. Clin Orthop Relat Res.1981;155:7-20.
5.
Berg P., Olsson U.Intra-articular injection of nonanimal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: a pilot study. Clin Exp Rheumatol.2004;22:300-306.
6.
Bloom BSDirect medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med.1988;84(2A):20-24.
7.
Carrabba MP, Paresce E., Angelini M., et al. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion . Eur J Rheumatol Inflamm. 1995;15:25-31.
8.
Conrozier T. , Bertin P., Mathieu P., et al. Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: an open-label, multicentre, pilot study. Clin Exp Rheumatol.2003;21:605-610.
9.
Day R., Brooks P., Conaghan PG, Petersen M., Multicenter Trial Group. A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intra-articular hyaluronan in osteoarthritis of the knee. J Rheumatol.2004;31:775-782.
10.
Dickson DJ, Hosie G., English JRA double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. JClin Res.2001;4:41-52.
Guyette TM, Bae H., Warren RF, Craig E., Wickiewicz TLResults of arthroscopic subacromial decompression in patients with subacromial impingement and glenohumeral degenerative joint disease. J Shoulder Elbow Surg.2002;11:299-304.
13.
Hinton R., Moody RL, Davis AW, Thomas SFOsteoarthritis: diagnosis and therapeutic considerations. Am Fam Physician. 2002;65: 841-848.
14.
Huskisson EC , Donnelly S.Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatol.1999;38:602-607.
15.
Itokazu M., Matsunaga T.Clinical evaluation of high-molecular-weight sodium hyaluronate for the treatment of patients with periarthritis of the shoulder. Clin Ther.1995;17:946-955.
16.
Jubb RW, Piva S., Beinat L., Dacre J., Gishen P.A 1-year, randomised, placebo (saline)-controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract. 2003;57:467-474.
17.
Leardini G. , Perbellini A., Franceschini M., Mattara L.Intra-articular injections of hyaluronic acid in the treatment of painful shoulder. Clin Ther.1988;10:521-526.
18.
Lippitt S., Harryman D II, Matsen FA III.A practical tool for evaluating shoulder function: the Simple Shoulder Test . In: Matsen FA III, Fu F, Hawkins RJ, eds. The Shoulder: A Balance of Mobility and Stability. Rosemont, Ill: American Academy of Orthopaedic Surgeons;1993:501-518.
19.
Lohmander LS , Dalen N., Englund G., et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Ann Rheum Dis.1996;55:424-431.
20.
Lussier A., Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Medicis R.Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol.1996;23:1579-1585.
21.
Migliore A. , Martin LS, Alimonti A., Valente C., Tormenta S.Efficacy and safety of viscosupplementation by ultrasound-guided intra-articular injection in osteoarthritis of the hip . Osteoarthritis Cartilage.2003; 11:305-306.
22.
Migliore A. , Tormenta S., Martin LS, et al. Open pilot study of ultrasound-guided intra-articular injection of hylan G-F 20 (Synvisc) in the treatment of symptomatic hip osteoarthritis. Clin Rheumatol.2005;24:285-289.
23.
Moreland LWIntra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanism of action. Arthritis Res Ther. 2003;5:54-67.
24.
Neustadt DHLong-term efficacy and safety of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Clin Exp Rheumatol.2003;21:307-331.
25.
Peyron JG, Balazs EAPreliminary clinical assessment of Na-hyaluronate injection into human arthritic joints. Pathol Biol (Paris). 1974;22: 731-736.
26.
Pleimann JH , Davis WH, Cohen BE, Anderson RBViscosupplementation for the arthritic ankle . Foot Ankle Clin. 2002;7:489-494.
27.
Raynauld JP , Torrance G., Band P., et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage. 2002;10:506-517.
28.
Rovetta G., Monteforte P.Intra-articular injection of sodium hyaluronate plus steroid verses steroid in adhesive capsulitis of the shoulder. Int J Tissue React.1998;20:125-130.
29.
Scale D., Wobig M., Wolpert W.Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res.1994;55:220-232.
30.
Tamai K., Mashitori H., Ohno W., Hamada J., Sakai H., Saotome K.Synovial response to intra-articular injections of hyaluronate in frozen shoulder: a quantitative assessment with dynamic magnetic resonance imaging. J OrthopSci.2004;9:230-234.
31.
Vad VB, Sakalkale D., Sculco TP, Wickiewicz TLRole of hylan G-F 20 in treatment of osteoarthritis of the hip joint. Arch Phys Med Rehabil.2003;84:1224-1226.
32.
Waddell DD, Bricker D.Clinical experience with the effectiveness and tolerability of hylan G-F 20 in 1047 patients with osteoarthritis of the knee. J Knee Surg.2006;19:19-27.
33.
Watterson JR , Esdaile JMViscosupplementation: therapeutic mechanisms and clinical potential in osteoarthritis of the knee. J Am Acad Orthop Surg.2000;8:277-284.
34.
Wobig M., Beks P., Dickhut A., et al. Open-label multicenter trial of the safety and efficacy of viscosupplementation with hylan G-F 20 (Synvisc) in primary osteoarthritis of the knee. J Clin Rheumatol.1999;5:S24-S31.
35.
Wobig M., Dickhut A., Maier R., Vetter G.Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther.1998;20:410-423.
